

Identification of bioactive glucose-lowering compounds of methanolic extract of *Hodgsonia heteroclita* fruit pulp

Talambedu Usha¹, Arvind Kumar Goyal^{2,3}, Derhasat Narzary³, Lokesh Prakash⁴, Gulshan Wadhwa⁵, Dinesh Babu⁶, Divya Shanmugarajan¹, Sushil Kumar Middha^{1*}

¹DBT-BIF Facility, BT-Finishing School, Science Research Centre, Department of Biochemistry and Biotechnology, Maharani Lakshmi Ammanni College for Women, Bengaluru-560012, Karnataka, India,

²Centre for Bamboo Studies, Bodoland University, Kokrajhar-783370, Bodoland Territorial Area Districts (BTAD), Assam, India, ³Department of Biotechnology, Bodoland University, Kokrajhar-783370,

BTAD, Assam, India, ⁴Department of Biochemistry, CPGS, Jain University, Jayanagar, Bangalore 560011, India; ⁵Biotechnology Information Centre, Department of Biotechnology, Govt. of India, New Delhi, India

⁶Heymans Institute of Pharmacology, Faculty of Medicine and Health Sciences, Ghent University, Gent, Belgium

TABLE OF CONTENTS

1. Abstract
2. Introduction
3. Materials and methods
 - 3.1. Plant material collection and extraction, and in-vitro studies
 - 3.2. In vitro antioxidant activity and free radical scavenging activity (DPPH method)
 - 3.3. Ferric reducing power assay
 - 3.4. Liquid chromatography-mass spectroscopy (LC-MS) analysis
 - 3.5. In silico studies and molecular docking for the binding mode of the inhibitors
 - 3.6. Molecular dynamics simulation
 - 3.7. In vivo animal studies
 - 3.7.1. Experimental design for deciphering anti-diabetic activity
 - 3.8. Statistical analysis
4. Results and discussions
 - 4.1. Anti-oxidant activity
 - 4.2. LC-MS analysis
 - 4.3. Virtual screening and docking
 - 4.4. Dynamics and simulation
 - 4.5. In vivo animal studies
5. Conclusion
6. Acknowledgments
7. References

1. ABSTRACT

We have investigated the anti-oxidative and glucose-lowering effects of 70% methanolic extract of *H. heteroclita* fruit pulp (MHE). Anti-oxidative property of MHE was assessed by free radical scavenging assays and compound level screening by LC-MS profiling. *In silico* analysis and *in-vivo* preclinical validation were also performed using molecular docking and alloxan-induced diabetic model, respectively. MHE showed high anti-oxidant activity in DPPH radical scavenging assay with an IC₅₀ of 0.37 µg/mL. The LC-MS profile of MHE substantiated

the presence of *p*-hydroxy acids including benzoic, salicylic, *p*-coumaric, *o*-coumaric, caffeic, protocatechuic, gentisic, 2,4-dihydroxybenzoic, gallic, vanillic, syringic, and ferulic acids. Among these, caffeic acid was the most likely compound to interact with 1R0E at Val⁷⁰, Ala⁸³, Lys⁸⁵, Gly⁹⁷, Asp¹³³, Val¹³⁵, Leu¹⁸⁸, Cys¹⁹⁹, and Asp²⁰⁰, and with 1Q4L at Ile⁶², Ala⁸³, Asp¹³³, Tyr¹³⁴, Val¹³⁵, Arg¹⁴¹, and Val¹⁷⁰. Treatment of rats with MHE showed significant reduction in serum glucose levels as compared to control rats. Taken together, the results show that MHE has compounds

with anti-diabetic effect, which could be partially due to the anti-oxidant effects of the active components in MHE.

2. INTRODUCTION

Glycogen synthase kinase-3 β (GSK-3 β), a well-known modulator of glycogen metabolism, is now established as a Ser/Thr protein kinase having been playing a major role in several pathways including apoptosis, initiation of protein synthesis, cell proliferation and differentiation (1–3). Numerous studies have reported various inhibitors of GSK-3 β (3–5). Henriksen and Dokken (2006) indicated that an over-expression of GSK-3 in skeletal muscle of rodent models of obesity and obese type 2 diabetic humans are allied with an impaired capability of insulin to trigger glucose clearance and glycogen synthase (6). This makes GSK-3 β a relevant target for diabetes.

Popularly celebrated as Chinese lard plant, *Hodgsonia heteroclita* (Roxb.) Hook. f. & Thomson (Cucurbitaceae) is found in India, China, Bangladesh, Malaysia and Nepal (7–9). In India, *H. heteroclita* is found in the hills of the entire North-Eastern province and is an important folklore medicinal plant indispensable for the life of the tribes of this region (10). The seed oil (62–71%) is commonly used in cooking and beverages by the tribes of Assam (Karbi and Dimas) (10). The tribes of Arunachal Pradesh (Nishi), Meghalaya (Jaintia, Garo and Khasi) and Mizoram (Chakma, Hajong, Tongbe and Riang) use the roasted seeds of *H. heteroclita* to garnish food items. The crushed seeds of *H. heteroclita* are reported, though not scientifically validated, for the treatment of intestinal worms by Manipuri tribes (Naga and Kuki) and Nagaland tribes (Angamis and Rengma) (11). In Nagaland, Angamis and Rengma tribes apply the fruit pulp of *H. heteroclita* to cure bacterial infections of feet. Seed powder is given in indigestion and stomach pain. The Bhil, Chaimal, Mizel and Orang tribes of Tripura apply leaf juice on fresh cuts and wounds to stop bleeding and also on ulcers (12). The oil is also used as a base for medicines in North-Eastern India. Additionally, the roasted endosperm of *H. macrocarpa*, another species of the *Hodgsonia* genus, is given to the women and children as energetic food by mixing with other food items (13,14).

H. heteroclita (HH) is locally known as Hagrani jwgwnar among the Bodos and known for its ethno-botanical values (15). In their letter to editor, Usha *et al.* (2017) indicated HH for its anti-diabetic activity (16). Swargiary and his coworkers (2013) recorded the uses of *H. heteroclita* fruit pulp by Bodo tribes to control diabetes (17). Though different parts of the plant were recorded for its myriad of applications as traditional medicine, there has been no scientific evidence that

validate its conventional values till date. Therefore, this plant virtually remains unexplored on scientific grounds. The current study is an attempt to identify the bioactive compounds in the methanolic extract of *H. heteroclita* fruit pulp (MHE) using liquid chromatography-mass spectroscopy (LC-MS) and the probable mechanism using *In silico* tools by identifying the correct binding mode of the compounds investigated in this study using computer-aided molecular modeling techniques.

3. MATERIALS AND METHODS

3.1. Plant material collection and extraction, and in-vitro studies

H. heteroclita fruits were collected from the forest of Kokrajhar District, Bodoland Territorial Area Districts (BTAD), Assam, India, during November–December, 2013. After confirmation by a plant taxonomist a voucher specimen (Voucher No. DBT/BU/001) was deposited at the Botany Department, Bodoland University, Assam, India.

The collected fruits were thoroughly washed with distilled water, air dried and stored in a cool and dark place. Then, the dried pulps were sliced, and powdered using mechanical grinder. 10 g powdered sample was subjected to Soxhlet apparatus using 70% methanol (v/v) in 1:15 m/v ratio (18). The extraction was carried out at boiling temperature for 6 h for three cycles. The extract was evaporated under pressure at 50°C to obtained constant weight and stored at 4°C until required. Before use, MHE was dissolved in double-distilled water (DDW) at desired concentrations.

3.2. In vitro antioxidant activity and free radical scavenging activity (DPPH method)

The anti-oxidant activity of MHE along with ascorbic acid reference standard was assessed for free radical scavenging effect of the stable DPPH free radical as previously reported (19). The discoloration was measured at 517 nm using Thermo UV1 spectrophotometer. In case of control, the solvent methanol was taken instead of the plant extract sample. Percentage scavenging of the DPPH free radical was measured using the following equation:

$$\text{scavenging effect (\%)} = \frac{(A_0 - A_1)}{A_0} \times 100$$

where A_0 was the absorbance of the control and A_1 was the absorbance in the presence of the sample.

3.3. Ferric reducing power assay

The method of Oyaizu (1986) was used to determine the reducing power of MHE. Different

concentrations of MHE extract (0.2–2.0 mg/mL) in phosphate buffer (2.5 mL, 0.2 M, pH 6.6) and potassium ferricyanide [$K_3Fe(CN)_6$] (2.5 mL, 1%) was mixed (20). The mixture was incubated at 50°C for 20 min. A portion (2.5 mL) of TCA (10%) was added to the mixture, which was then centrifuged at 3,000 rpm for 10 min. The upper layer of the solution (2.5 mL) was mixed with DDW (2.5 mL) and $FeCl_3$ (0.5 mL, 0.1%), and the absorbance was recorded at 700 nm. Butyl hydroxyl toluene (BHT) and phosphate buffer (pH 6.6) were used as a reference standard and blank, respectively.

3.4. Liquid chromatography-mass spectroscopy (LC-MS) analysis

Derivatization procedure: A small amount of concentrated crude methanol extract was taken in a separating funnel and shaken by adding water and ethyl acetate in the ratio of 1:4. The upper layer was collected and concentrated in a rotary evaporator to about 1.5 mL. Added 100 μ L of N, O-Bis(trimethylsilyl) trifluoroacetamide and trimethyl chlorosilane (BSTFA+TMCS) and 20 μ L pyridine, and heated at 60°C for 30 min. From the layers which are separated from the crude extracts, a small amount of the extract was taken and evaporated out totally. To this, acetonitrile was added and the filtrate was added to 50 μ L BSTFA+TMCS solution. Solution was heated at 60°C at water bath for 30 min. The cooled solution was filtered using 0.45 μ membrane filter to a vial (21).

LC-MS Analysis: LC-MS analysis was carried out on a PerkinElmer TurboMass Spectrophotometer (Norwalk, CTO6859, USA) which includes a PerkinElmer Auto sampler XLGC. The column used was Perkin-Elmer Elite - 5 capillary column measuring 30 m \times 0.25 mm with a film thickness of 0.25mm composed of 95% dimethyl polysiloxane. The carrier gas used was Helium at a flow rate of 0.5 mL/min. 1 μ L sample injection volume was utilized. The inlet temperature was maintained as 250°C. The oven temperature was programmed initially at 110°C for 4 min, then an increase to 240°C, and then programmed to increase to 280°C at a rate of 20°C ending with a 5 min. Total run time was 90 min. The MS transfer line was maintained at a temperature of 200°C. The source temperature was maintained at 180°C. LC-MS was analyzed using electron impact ionization at 70eV and data was evaluated using total ion count (TIC) for compound identification and quantification. The spectrums of the components were compared with the database of spectrum of known components stored in the LC-MS library. Measurement of peak areas and data processing were carried out by Turbo-Mass-OCPTVS-Demo SPL software. The compounds detected in MHE using LC-MS were further followed with *In silico* studies to know the interaction between GSK-3 β and the best possible target.

3.5. *In silico* studies and molecular docking for the binding mode of the inhibitors

The investigation for the possible binding approach of the natural compounds to GSK-3 β is an effort to develop a potent GSK-3 β inhibitor. Initially, after assessing X-ray crystal structures of GSK-3 β , there are roughly two types of structures available in protein data bank (PDB), based on the side chain conformation of residue Phe⁶⁷ and Arg¹⁴¹ as previously reported by Kim *et al.* (2009). The possible reason of these conformation changes is because of Gly-rich loop present in GSK-3 β structures (22). The author had grouped PDB structures as 1R0E like (in pink) and 1Q4L like (in green) as shown in Figure 1. The active site was considered on the basis of previous literature (23).

The binding mode of PDB structures (1R0E and 1Q4L) were considered for docking with predefined binding site amino acid residues like Asp¹³³, Val¹³⁵, Leu¹³², Lys⁸⁵ and Gly⁹⁷. The LC-MS generated compounds (ligands) were docked into the binding site of GSK-3 β (1R0E and 1Q4L). Docking was conducted using C-DOCKER algorithm with a set of virtually screened ligands from ADMET as listed in Table 1. The receptors and ligands were prepared as per the prescribed protocol of C-DOCKER in Discovery Studio 3.5. and reported previously (21). Additionally, simulation annealing was introduced to simulate the complex and the system was heated at 500k target temperature, followed by cooling at 500k. Finally, the interaction between the active site's amino acid and the compound's non-bond interactions was analyzed using the view interaction tool in Discovery Studio 4.5 Visualizer.

3.6. Molecular dynamics simulation

Finally, the best screened pose of the docked complex from docking study and apoprotein was subjected to nanoscale simulation process using Discovery Studio 3.5 with the integration of leap-frog Verlet and SHAKE constraint. The simulation was executed in five different steps for apoprotein and protein-ligand complex by applying CHARMM force field followed by minimization with 1000 steps using steepest descent and conjugate gradient, respectively. Each individual system was heated from 50k to 350k with 4ps of simulation time. Consequently, the system was equilibrated for 40ps of simulation time to achieve even distribution system with degrees of freedom. Finally, production in the canonical (NVT) ensemble was subjected with equal Tmass and Pmass at 300k for 1600ps. Additionally, spherical-cutoff method of electrostatics was implemented to study the all non-bonded energy without using periodic boundary condition. Periodic boundary conditions enable a simulation to be performed using a relatively small




Figure 1. Two groups of GSK-3β structures are shown with respect to the residue Phe67 and Arg141, A&C: 1R0E-like (Pink), B&D:1Q4L-like (Green) E&F: Superimposition of 1R0E-like and 1Q4L-like.

Table 1. ADME and toxicity descriptors of the compounds

| Compounds | Solubility | BBB | Absorption | CYD2D6 | Hepatotoxic | CPR TD50 (mg/kg_ body_ weight/day | AM | Rat oral LD50 | RIT LC50 (mg/ m3/h) | Daphnia EC50 (mg/l) |
|--------------------------|------------|-----|------------|--------|-------------|---|----|------------------|------------------------------|---------------------------|
| Vanillic acid | 4 | 3 | 0 | FALSE | FALSE | 77.027 | NM | 2.38993 | 4,296.55 | 22.6022 |
| Caffeic acid | 4 | 3 | 0 | FALSE | FALSE | 188.775 | NM | 1.85416 | 1,572.25 | 40.9906 |
| Ferulic acid | 4 | 3 | 0 | FALSE | FALSE | 303.519 | NM | 1.63276 | 1,161.35 | 17.4517 |
| p-Coumaric acid | 4 | 3 | 0 | FALSE | FALSE | 122.354 | NM | 2.29775 | 3,135.41 | 13.0734 |
| 2,4Dihydroxybenzoic acid | 4 | 3 | 0 | FALSE | TRUE | 101.131 | NM | 1.29284 | 1,317.73 | 30.8305 |
| Gallic acid | 4 | 3 | 0 | FALSE | TRUE | 148.569 | NM | 1.60156 | 1,572.25 | 29.2337 |
| Gentisic acid | 4 | 3 | 0 | FALSE | TRUE | 895.558 | NM | 1.65801 | 1,103.80 | 21.3151 |
| o-Coumaric acid | 4 | 3 | 0 | FALSE | TRUE | 326.405 | NM | 1.35061 | 1,162.89 | 14.8876 |
| p-Hydroxy benzoic acid | 4 | 3 | 0 | FALSE | TRUE | 199.666 | NM | 1.36500 | 1,548.41 | 25.0096 |
| Protocatechuic acid | 4 | 3 | 0 | FALSE | TRUE | 147.19 | NM | 0.43193 | 5,342.90 | 43.2612 |
| Salicylic acid | 4 | 3 | 0 | FALSE | TRUE | 547.824 | NM | 1.82047 | 1,469.73 | 53.41 |
| Syringic acid | 4 | 3 | 0 | FALSE | TRUE | 47.0074 | NM | 1.84410 | 4,552.30 | 12.1932 |

AM= Ames mutagenicity ,NM= Non-Mutagen ,CPR= Carcinogenicity/Potency, Rat RIT= Rat inhalation toxicity, Absorption level 0 as Good Absorption, BBB(Blood Brain barrier) level 3 shows low to Medium, Solubility level 4 as optimal

Table 2. DPPH scavenging activity of methanolic extract of *H. heteroclita* fruit pulp (MHE) compared to ascorbic acid as standard

| Concentration in µg/mL | MHE | Ascorbic acid |
|------------------------|------------|---------------|
| 20 | 22.99±1.11 | 21.12±1.82 |
| 40 | 23.03±2.92 | 28.98±0.99 |
| 80 | 28.65±0.99 | 45.98±2.88 |
| 120 | 29.65±2.98 | 60.16±2.96 |
| 160 | 38.31±1.93 | 65.9±4.74 |
| 200 | 48.15±3.32 | 71.13±3.87 |

number of particles in such a way that the particles experience forces as though they were in a bulk solution.

3.7. *In vivo* animal studies

The male *Wistar albino* rats weighing 140–160 g were housed under laboratory conditions of light and dark cycles of 7:00 am to 7:00 pm, temperature (25°C ± 2°C), relative humidity (68% ± 1%) and provided standard rat pellet (Lipton India Ltd., Bangalore, India) and tap water *ad libitum*. The study protocol was approved and cleared by internal ethical approval committee (IEAC) of Maharani Lakshmi Ammanni College (1368/ac/10/CPCSEA), Bangalore, India.

3.7.1. Experimental design for deciphering anti-diabetic activity

After several days of acclimatization, alloxan diluted in citrate buffer (150 mg/mL, 0.1 M, pH 4.0) was injected intraperitoneally to the experimental animals, following overnight fasting. Two days later, the diabetic state was confirmed by blood samples collected from tail vein method and the fasting blood glucose level was measured by Accu-Chek (Roche, USA) once a week. Diabetic rats were divided into 6 groups (n = 8 per group), avoiding any inter-group differences in blood glucose levels, including a normal group (NL), a positive control (diabetic glibenclamide; DG), negative control (not treated; DC), animals fed orally using 16g ball point needle with low (20 mg/kg bw/mL) and high dosage (40 mg/kg bw/mL) of extract (LH & HH; suspended in 0.1% di-methyl sulfoxide (DMSO)). The normal and control diabetic group was given 0.1% of DMSO. Diabetic rats treated with standard drug insulin (DI) (2 units/kg of bodyweight) (Insugen, Biocon, India) daily intraperitoneally for 45 days.

3.8. Statistical analysis

The three times repeated results were expressed as mean ± standard error of the mean (SEM) and analyzed statistically using two-way analysis of variance (ANOVA) using GraphPad Prism

software and $p < 0.05$ was considered to be statistically significant.

4. RESULTS AND DISCUSSIONS

Plants have been a source of medicine since the time immemorial. Different plants are key ingredients of many herbal formulations that fight against various human related health ailments. Therefore, detailed study of plant materials is of prime focus for the advancement and quality control of folk formulations. Keeping this in mind, the present study was undertaken to evaluate the anti-oxidant activity and identify the bioactive compounds present in the methanolic extract of *H. heteroclita* fruit pulp (MHE) native to Bodoland, India using LC-MS, to find out probable inhibitors such as salicylic acid, ferulic acid, vanillic acid, caffeic acid (Table 3) of the GSK-3 β and their mechanistic approach to treat diabetic conditions followed by *in vivo* validation using alloxan-induced diabetic animals.

4.1. Anti-oxidant activity

The anti-oxidant effect of MHE as assessed by its ability to scavenge DPPH radical was found to be with EC₅₀ of 6.03 µg/mL as compared to the reference anti-oxidant ascorbic acid (EC₅₀=3.75 µg/mL). The radical scavenging pattern of MHE was dose dependent (Table 2). The reducing power of MHE showed better reducing effect as compared to the standard BHT (Figure 2). The observed effect could be due to the presence of the mixture of compounds present in MHE. Moreover, the extract demonstrated strong radical scavenging activity comparable to the synthetic anti-oxidant BHT, which could be possibly due to the presence of phenolic compounds in the extract.

4.2. LC-MS analysis

The phyto-constituents identified from MHE with their IUPAC name, molecular formula, common name, chemical structure, retention time (RT), and concentration (peak area %) using LC-MS are represented in Table 3. Among the




Figure 2. Reducing power assay methanolic extract of *H. heteroclita* fruit pulp compared to BHT as standard.

identified phyto-compounds, *p*-hydroxybenzoic acid (24), salicylic acid (25), protocatechuic acid (26), *p*-coumaric acid (25), caffeic acid (27), vanillic acid (28), ferulic acid (28), and gallic acid (29, 30) have proven anti-diabetic activity. In addition to anti-diabetic activity, *p*-hydroxybenzoic acid is also reported for its anti-fungal, anti-mutagenic, estrogenic, and anti-microbial activities (31). Salicylic acid is known for its keratolytic, anti-inflammatory, anti-pyretic, analgesic, anti-septic and anti-fungal properties (31). Used as a flavoring ingredient in foods and drugs, *p*-coumaric acid and gentisic acid have noted anti-cancerous properties (31–33). Magnani *et al.* (2014) indicated the anti-oxidant and prevention of premature aging activities of caffeic acid (34). Prior studies have shown protocatechuic acid as a promising compound imparting various pharmacological activities like anti-oxidant, analgesic, anti-inflammatory, anti-rheumatic and anti-arthritis activity (35). Gentisic acid inhibits low-density lipoprotein oxidation in human plasma (36). 2,4-dihydroxy benzoic acid has thyroid peroxidase inhibitory effect and snake venom 5'-nucleotidase inhibitor vanillic acid has proven astringent, antineoplastic and bacteriostatic activities (31). Gallic acid possesses anti-melanogenic (37) and antioxidant properties (30). Ferulic acid has therapeutic potentials against various diseases like cancer, diabetes, cardiovascular dysfunction, neurodegenerative and inflammatory diseases, and in aging. It has a













strong anti-oxidant property (38). Syringic acid has anti-oxidant, anti-bacterial and hepatoprotective activities. (31). All identified compounds in MHE are known for its pharmacological activities and shown in Table 3.

4.3. Virtual screening and docking

The receptor influenced to bind compounds with highest dock score and favorable bonding is considered as the best receptor. The compounds caffeic acid, vanillic acid, ferulic acid and *p*-coumaric acid satisfies ADMET property, and found to be inside 95% and 99% confidence ellipsoids for absorption and blood brain barrier (BBB) (Figure 3). ADMET plot was found to be non-hepatotoxic and non-inhibitors of metabolizing enzyme (CYP2D6, a class of Cytochrome 450 class of enzyme). This specifies that these compounds found to be well-metabolized in Phase-I metabolism. Furthermore, these screened compounds show good absorption (Table 1), has the potential to cross the BBB with optimal solubility. Perhaps, all the compounds have shown a non-mutagenic effect when subjected to Ames test in addition to satisfying RO5 violations and Veber's rules of drug-likeness property but are ruled out in ADMET screening.

Validation of docking conformation with default bound ligand of 1R0E compared with docked poses of caffeic acid (31.37) forms 11 favorable non-bond interaction with least RMSD deviation of

Table 3. Phytochemical constituents of *Hodgsonia heteroclita* fruit pulp identified using LC-MS analysis

| Sl. No | IUPAC Name Molecular Formula Common Name | Chemical Structure | RT (min) | Height | Area | Peak Area% |
|--------|--|---|----------|--------|--------|------------|
| 1 | 4-hydroxybenzoic acid $\text{HO-C}_6\text{H}_4\text{-COOH}$ p-Hydroxy benzoic acid |  | 3.41 | 217 | 36.69 | 14.68 |
| 2 | 2-hydroxybenzoic acid $\text{C}_6\text{H}_4(\text{OH})\text{COOH}$ Salicylic acid |  | 6.77 | 530 | 213.23 | 85.32 |
| 3 | (2-hydroxyphenyl) prop-2-enoic acid $\text{C}_9\text{H}_8\text{O}_3$ o-Coumaric acid |  | 5.22 | 732 | 62.60 | 73.55 |
| 4 | (E)-3-(4-hydroxyphenyl)-2-propenoic acid $\text{C}_9\text{H}_8\text{O}_3$ p-Coumaric acid |  | 5.45 | 441 | 22.52 | 26.45 |
| 5 | 3-(3,4-dihydroxyphenyl)-2-propenoic acid $\text{C}_9\text{H}_8\text{O}_4$ Caffeic acid |  | 4.70 | 393 | 15.18 | 100.00 |
| 6 | 3,4-Dihydroxybenzoic acid $\text{C}_7\text{H}_6\text{O}_4$ Protocatechuic acid |  | 1.35 | 3805 | 871.80 | 95.89 |
| 7 | 2,5-dihydroxybenzoic acid $\text{C}_7\text{H}_6\text{O}_4$ Gentisic acid |  | 2.64 | 60 | 11.93 | 1.31 |
| 8 | 2,4-dihydroxybenzoic acid $\text{C}_7\text{H}_6\text{O}_4$ 2,4-Dihydroxybenzoic acid (β -Resorcylic acid) |  | 3.42 | 157 | 25.42 | 2.80 |
| 9 | 4-hydroxy-3-methoxybenzoic acid $\text{C}_8\text{H}_8\text{O}_4$ Vanillic acid |  | 4.53 | 156 | 25.86 | 100 |
| 10 | 3,4,5-trihydroxybenzoic acid $\text{C}_7\text{H}_6\text{O}_5$ Gallic acid |  | 0.99 | 327 | 20.06 | 100 |
| 11 | (E)-3-(4-hydroxy-3-methoxy-phenyl)prop-2-enoic acid $\text{C}_{10}\text{H}_{10}\text{O}_4$ Ferulic acid |  | 5.69 | 128 | 23.34 | 100 |
| 12 | 4-hydroxy-3,5-dimethoxybenzoic acid $\text{C}_9\text{H}_{10}\text{O}_5$ Syringic acid |  | 6.23 | 89 | 36.79 | 100 |




Figure 3. ADMET Plot.

0.037Å for pose number 10, but docking of caffeic acid (28.04) with 1Q4L forms 10 favorable interaction of RMSD deviation of $>0.05\text{\AA}$ for pose number 7. So, we have considered caffeic acid which shows the least deviation with 1R0E as a better target for GSK-3 β inhibitor. RMSD deviation of other compounds like vanillic acid, ferulic acid and p-coumaric acid was $>0.090\text{\AA}$ (Figure 1). Bond-forming residues in case of the compound caffeic acid with 1R0E are Val¹⁷⁰, Ala⁸³, Lys⁸⁵, Gly⁹⁷, Asp¹³³, Val¹³⁵, Leu¹⁸⁸, Cys¹⁹⁹, Asp²⁰⁰ and caffeic acid with 1Q4L are Ile⁶², Ala⁸³, Asp¹³³, Tyr¹³⁴, Val¹³⁵, Arg¹⁴¹, Val¹⁷⁰ as shown in Figure 4 (A & B) and (C & D), respectively.

4.4. Dynamics and simulation

The best pose of 1R0E–caffeic acid complex from docking and its apo-form of protein (1R0E) were subjected to 1.6 ns MD simulations using Discovery Studio 3.5. The stability of the protein complex and its folding pattern was studied using root-mean-square deviation (RMSD), root-mean-square fluctuation (RMSF), and Radius of gyration (R_g). RMSD of the 1R0E–caffeic acid complex and apoprotein were observed to oscillate steadily within the range about 2.2\AA - 2.6\AA along the simulation. After an initial rise in the RMSD, the system converges around 750 ps, indicating the stability and equilibration state of the proteins. Backbone deviation of apoprotein was much observed at a time interval of 400 to 600 ps, whereas, in a case

of the bound complex there is no much deviation noticed (Figure 5). RMSD results indicated that the complex did not experience large conformational and structural changes, and it was stable due to the RMSD evolved within the acceptable range (39). RMSF studies are constructive in the measurement of C α average atomic mobility in dynamics process. In agreement with the studies of the RMSF, much deviation was observed for apoprotein than ligand-protein complex (40) (Figure 6). The R_g was also calculated to analyze the folding pattern of the protein during simulation and it is defined as the root mean square distance of the collection of atoms from their common center of gravity. The results of gyration of apoprotein shows that the change in pattern at time interval of 50 to 350 ps and not much deviation was observed in ligand -protein folding pattern (Figure 7). Overall simulation of 1R0E–caffeic acid complex had shown more stability (-19827.50 kcal/mol) than an apo-form of protein (-19592.21 kcal/mol).

4.5. In vivo animal studies

Figure 8 depicted the fasting blood glucose (FBG) in different experimental groups. Prior to alloxan administration, blood glucose levels of all the experimental rats were checked and the animals were selected based on FBG that was not significantly different. However, there was a significant increase (more than 220 mg/dL) in FBG level was noticed after 72 h administration of alloxan and rats were considered




Figure 4. (A&B) 1R0E docked with Caffeic acid, (C&D) 1Q4L docked with Caffeic acid.




Figure 5. RMSD plot of 1R0E-Caffeic acid complexes and 1R-apo protein, during 1600 ps simulations.




Figure 6. RMSF plot of 1R0E-Caffeic acid complexes and 1R-apo protein, during 1600 ps simulations.




Figure 7. Radius of gyration plot of 1R0E-Caffeic acid complexes and 1R-apo protein, during 1600 ps simulations.




Figure 8. Effect of methanolic extract of *H. heteroclita* extract on glucose level in experimental animals.

diabetic (29). Although a significant reduction in glucose level was marked from the second week onward, a decrease in FBG was more evident on the third week in the group receiving a high dose of MHE (HH) and found significant ($p < 0.0.5$) as compared with DC rats. Administration of LH, HH and DG led to significant decrease in blood glucose levels by 45, 52 and 47% on the 42nd day when compared to diabetic animals (Figure 8). The anti-diabetic action could be due to the presence of polyphenolic compounds present in MHE. Additionally, the pronounced effect could be due to the presence of caffeic acid as indicated by *In silico* study demonstrated before.

5. CONCLUSION

In conclusion, the results of the anti-oxidant effect of methanolic extract of *H. heteroclita* fruit pulp point out to a strong protective activity against free radicals and oxidative agents *in vitro*. Thus, it might be possible that the anti-hyperglycaemic property of MHE could be partially contributed by the anti-oxidant effects of the active components present in the fruit pulp of *H. heteroclita* and caffeic acid

could be responsible for the anti-diabetic activity. The current study is the first scientific report with compound detection and anti-oxidant activity of methanolic extract of *H. heteroclita* fruit pulp as well as mechanistic evidence for its anti-diabetic property followed by *in-vivo* validation.

6. ACKNOWLEDGMENTS

TU, AKG, DS and DN performed the experiments, prepared the manuscript, and analyzed the data. LP, GW and DB performed some of the experiments and wrote a part of the manuscript. SKM conceived the idea, designed and coordinated the experiments, improved the manuscript and generated funding. The infrastructure support from the DBT-BIF Facility and Bt-Finishing School to Maharani Lakshmi Ammanni College for Women (MLACW) is gratefully acknowledged. The authors are thankful to the management for providing animal house facility, MLACW, Bangalore, India. The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

7. REFERENCES

1. A Kuzmanic, B Zagrovic: Determination of ensemble-average pairwise root mean-square deviation from experimental B-factors. *Biophysics J* 98, 861–71 (2010)
DOI: 10.1016/j.bpj.2009.11.011
PMid:20197040 PMCid:PMC2830444
2. AK Goyal, SK Middha, A Sen: Evaluation of the DPPH radical scavenging activity, total phenols and antioxidant activities in Indian wild *Bambusa vulgaris*. *J Nat Phrama* 1, 40–45 (2010)
DOI: 10.4103/2229-5119.73586
3. AK Goyal, SK Middha, T Usha, A Sen: Analysis of toxic, antidiabetic and antioxidant potential of *Bambusa balcooa* Roxb. leaf extracts in alloxan-induced diabetic rats. *3 Biotech* 7, 120 (2017)
DOI: 10.1007/s13205-017-0776-8
4. A Swargiary, H Boro, BK Brahma, S Rahaman: Ethno-Botanical Study of Anti-Diabetic Medicinal Plants used by the Local People of Kokrajhar District of Bodoland Territorial Council, India. *J Med Plants Studies* 1(5), 51–58 (2013)
5. BD Sharma, DK Hore, S Mandal: *Hodgsonia macrocarpa*-a non-conventional edible fat and protein source, *Indian J Plant Genet Resour* 4(2), 82–85 (1991)
6. C Coman, OD Rugina, C Socaciu: Plants and natural compounds with antidiabetic action. *Not Bot Horti Agrobo* 40(1), 314–25 (2012)
7. C Magnani, VLB Isaac, MA Correa, HRN Salgado: Caffeic acid: a review of its potential use in medications and cosmetics. *Anal Methods* 6(10), 3203–10 (2014)
DOI: 10.1039/c3ay41807c
8. D Narzary, SK Middha, Usha T, BK Brahma, AK Goyal: Comparative evaluation of phytochemical constituents of rind, pulp, and seed of *Hodgsonia heteroclita* fruit encountered in Kokrajhar district, BTAD, Assam, India. *World J Pharma Res* 6(4), 1629–36 (2005)
9. E Lindahl, B Hess, D van der Spoel: GROMACS 3.0.: a package for molecular simulation and trajectory analysis. *J Mol Model.* 7, 306–17 (2001)
DOI: 10.1007/s008940100045
10. EJ Henriksen, BB Dokken: Role of glycogen synthase kinase-3 in insulin resistance and type 2 diabetes. *Curr Drug Targets.* 7(11), 1435–41 (2006)
DOI: 10.2174/1389450110607011435
PMid:17100583
11. G-H Kuo, C Prouty, A DeAngelis, LQ Shen, DJ O'Neill, C Shah PJ Connolly, WV Murray, BR Conway, P Cheung, L Westover, M Srinivasan, AR Sudheer, VP Menon: Ferulic acid: therapeutic potential through its antioxidant property. *J Clin Biochem Nutr* 40(2), 92 (2007)
DOI: 10.3164/jcbrn.40.92
12. GRIN: *Hodgsonia heteroclita* information from NPGS/GRIN. Germplasm Resources Information Network. United States Department of Agriculture, USA (2007)
DOI: 10.1021/ja046049c
13. H Bregman, DS Williams, GE Atilla, PJ Carroll, E Meggers: An Organometallic Inhibitor for Glycogen Synthase Kinase3. *J Am Chem Soc* 126, 13594–95 (2004)
DOI: 10.1021/ja046049c
PMid:15493898
14. JA Bertrand, S Thieffine S, A Vulpetti, C Cristiani, B Valsasina, S Knapp, HM Kalisz, M Flocco: Structural Characterization of the GSK-3 β Active Site Using Selective and Non-selective ATP-mimetic Inhibitors. *J Mol Biol* 333, 393–07 (2003)
DOI: 10.1016/j.jmb.2003.08.031
PMid:14529625
15. JD Hooker: Flora of British India (reprinted in 1982), Vol. II, Bishen Singh Mahendra Pal Singh, Dehra Dun, 1982, 78.
16. J Witherington, V Bordas, A Gaiba, A Naylor, AD Rawlings, BP Slingsby, DG Smith, AK Takle, RW Ward: 6-Heteroaryl-pyrazolo (3,4-b) pyridines: Potent and Selective Inhibitors of Glycogen Synthase Kinase-3 (GSK-3) *Bioorg Med Chem Lett* 13, 3059–62 (2003)
DOI: 10.1016/S0960-894X(03)00646-2
17. JZ Xu, RA Look, KT Demarest, S Emanuel, SA Middleton, L Jolliffe, MP Beavers, X Chen: Synthesis and Discovery of Macrocyclic Polyoxygenated Bis-7-azaindolylmaleimides as a Novel Series of Potent and Highly Selective Glycogen Synthase Kinase-3 α Inhibitors. *J Med Chem* 46, 4021–31 (2003)

18. K Ashidate, M Kawamura, D Mimura, H Tohda, S Miyazaki, T Teramoto, Y Yamamoto, Y Hirata: Gentisic acid, an aspirin metabolite, inhibits oxidation of low-density lipoprotein and the formation of cholesterol ester hydroperoxides in human plasma. *Eur J Pharmacol* 513, 173–179 (2005)
DOI: 10.1016/j.ejphar.2005.03.012
PMid:15862799
19. KH Kim, I Gaisina, F Gallier, D Holzel, SY Blond, A Mesecar, AP Kozikowski: Use of Molecular Modelling, Docking, and 3D-QSAR Studies for the Determination of the Binding Mode of 3-Benzofuranyl-4-indolyl-maleimides as GSK-3 β Inhibitors. *J Mol Model* 15(12), 1463–79 (2009)
DOI: 10.1007/s00894-009-0498-x
PMid:19440740 PMCID:PMC2955516
20. L Meijer L, AL Skaltsounis, P Magiatis, P Polychronopoulos, M Knockaert, M Leost, XP Ryan, CA Vonica, A Brivanlou, R Dajani, C Crovace, C Tarricone, A Musacchio, SM Roe, L Pearl, P Greengard: GSK-3-selective inhibitors derived from Tyrian purple indirubins. *Chem Biol* 10, 1255–66 (2003)
DOI: 10.1016/j.chembiol.2003.11.010
21. MG Figueroa-Pérez, MA Gallegos-Corona, M Ramos-Gomez, R Reynoso-Camacho: Salicylic acid elicitation during cultivation of the peppermint plant improves anti-diabetic effects of its infusions. *Food Funct* 6(6), 1865–74 (2015)
DOI: 10.1039/C5FO00160A
PMid:25940690
22. MH Abdel-Wahab, MA El-Mahdy, MF Abd-Allah, GK Helal, F Khalifa, FMA Hamada: Influence of p-coumaric acid on doxorubicin-induced oxidative stress in rat's heart. *Pharmacol Res* 48 (5), 461–65 (2003)
DOI: 10.1016/S1043-6618(03)00214-7
23. M Oyaizu: Studies on products of browning reaction. *Jpn J Nutri Dietetics* 44(6), 307–15 (1986)
DOI: 10.5264/eiyogakuzashi.44.307
24. PK Arora, MW Hardas: *Hodgsonia heteroclite*- an oil rich cucurbit, *J Bombay Nat Hist Soc* 74, 559–61 (1976)
25. P Peungvicha, R Temsiririrrkul, JK Prasain, Y Tezuka, S Kadota, SS Thirawarapan, H Watanabe: 4-Hydroxybenzoic acid: a hypoglycemic constituent of aqueous extract of *Pandanus odoratus* root. *J Ethnopharmacol* 62(1), 79–84 (1998)
DOI: 10.1016/S0378-8741(98)00061-0
26. R Singh, MK Singh, LR Chandra, D Bhat, MS Arora, T Nailwal, V Pande: *In vitro* antioxidant and free radical scavenging activity of *Macrotyloma uniflorum* (Gahat dal.) from Kumauni region. *Int J Fund Applied Sci* 1, 7–10 (2012)
27. S Kakkar, S Bais: A Review on Protocatechuic Acid and Its Pharmacological Potential. *ISRN Pharmacol* Article ID 952943, 1–9 (2014)
DOI: 10.1155/2014/952943
PMid:25006494 PMCID:PMC4005030
28. S Khadem, RJ Marles: Monocyclic phenolic acids; hydroxy- and polyhydroxybenzoic acids: occurrence and recent bioactivity studies. *Molecules* 15(11), 7985–05 (2010)
DOI: 10.3390/molecules15117985
PMid:21060304
29. SK Middha, AK Goyal, SA Faizan, N Sanghamitra, BC Basistha, T Usha: *In silico*-based combinatorial pharmacophore modelling and docking studies of GSK-3 β and GK inhibitors of *Hippophae*. *J Biosci* 38(4), 805–14 (2013)
DOI: 10.1007/s12038-013-9367-y
PMid:24287660
30. SK Middha, T Usha, V Pande: HPLC evaluation of phenolic profile, nutritive content, and antioxidant capacity of extracts obtained from *Punica granatum* fruit peel. *Adv Pharmacol Sci* 2013, Article ID 296236, 1–6 (2013)
DOI: 10.1155/2013/296236
31. SK Middha, AK Goyal, A Bhardwaj, R Kamal, P Lokesh, HP Prashanth, G Wadwa, T Usha: *In silico* exploration of cyclooxygenase inhibitory activity of natural compounds found in *Myrica nagi* using LC-MS. *Symbiosis* 70: 169–178 (2016)
DOI: 10.1007/s13199-016-0417-8
32. SR Shairibha, M Rajadurai, NA Kumar: Effect of p-Coumaric Acid on Biochemical Parameters in Streptozotocin-Induced Diabetic Rats. *J Acad Indus Res* 3(5), 237–42 (2014)
DOI: 10.4103/2277-9175.185575

33. SY Hu: The economic botany of *Hodgsonia*. *Eco. Bot.* 18, 167–79 (1964)
DOI: 10.1007/BF02862714
34. The Wealth of India- A Dictionary of Indian Raw Materials & Industrial Products, Publication & Information Directorate, Council of Scientific and Industrial Research 5,102–03 (1959)
35. T Usha, SK Middha, D Narzary, BK Brahma, AK Goyal: *In silico* and *in-vivo* based scientific evaluation of traditional anti-diabetic herb *Hodgsonia heteroclita* fruit pulp used by bodo tribe in india. *Bangladesh J Pharmacol* 12(2), 165–66 (2017)
DOI: 10.3329/bjp.v12i2.31122
PMid:16644902
36. UJ Jung, MK Lee, YB Park, SM Jeon, MS Choi: Antihyperglycemic and antioxidant properties of caffeic acid in db/db mice. *J Phramcol Exp Ther* 318(2), 476–83 (2006)
DOI: 10.1124/jpet.106.105163
37. Y Semaming, P Pannengpetch, SC Chattipakorn, N Chattipakorn: Pharmacological Properties of Protocatechuic Acid and Its Potential Roles as Complementary Medicine. *Evid Based Complement Alternat Med.* 2015, Article ID 593902, 1–11(2015)
DOI: 10.1155/2015/593902
38. Y Shin-hwa: A preliminary study on the structure of seed shells and fruit coats in *Hodgsonia macrocarpa*. *Cong Acta Bot Yunnanica* 2, 10 (1981)
39. WY Ning, Li Cai Li, WZ Huai: Story of Lard Fruit (*Hodgsonia macrocarpa*), Books about the sacred sites of Chinese Academy of Science, Xishuangbanna, Tropical Botanical Garden, Hebei University Press, Baoding, 173–182 (2004)

Key Words: Diabetes, Treatment, *Bodo* tribe, LC-MS, *Hodgsonia heteroclita*

Send correspondence to: Dr. Sushil Kumar Middha, Department of Biotechnology and Biochemistry, MLACW, Bangalore 560012, Tel: 91–080-23360816, Fax: 91–080-23211020, E-mail: drsushilmiddha@gmail.com